Phenotype analysis of human cytochrome P450 2C9 polymorphism using a panel of fluorine-substituted benzo[h]quinolines as inhibitors of tolbutamide hydroxylation

Journal of Health Science

Volumn 52, Issue 6, 2006, Pages 821-824

  Matsuyama, Noriko ^a   Kato, Taka Aki ^a   Kimura, Kazunori ^a   Mizutani, Takaharu ^a   Saeki, Ken Ichi ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Aza polycyclic aromatic hydrocarbon; Cytochrome P450 2C9; Fluorine substitution; Inhibitor; Polymorphism

Indexed keywords

10 FLUOROBENZ[H]QUINOLINE; 3 FLUOROBENZ[H]QUINOLINE; 3,6 DIFLUOROBENZ[H]QUINOLINE; 5 FLUOROBENZ[H]QUINOLINE; 5,6 DIFLUOROBENZ[H]QUINOLINE; 6 FLUOROBENZ[H]QUINOLINE; 7,10 DIFLUOROBENZ[H]QUINOLINE; 9 FLUOROBENZ[H]QUINOLINE; BENZ[H]QUINOLINE DERIVATIVE; CYTOCHROME P450 2C9; ISOENZYME; QUINOLINE DERIVATIVE; TOLBUTAMIDE;

ARTICLE; CATALYSIS; DRUG HYDROXYLATION; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; IC 50; PHENOTYPE; SUBSTITUTION REACTION; WILD TYPE;

EID: 33845411879     PISSN: 13449702     EISSN: 13475207     Source Type: Journal    
DOI: 10.1248/jhs.52.821     Document Type: Article

References (12)

1. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J. and Trager, W. F. (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol., 5, 54-59.
2. Veronese, M. E., Mackenzie, P. I., Doecke, C. J., McManus, M. E., Miners, J. O. and Birkett, D. J. (1991) Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun., 175, 1112-1118.
3. Srivastava, P. K., Yun, C. H., Beaune, P. H., Ged, C. and Guengerich, F. P. (1991) Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol., 40, 69-79.
4. Veronese, M. E., Miners, J. O., Randles, D., Gregov, D. and Birkett, D. J. (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin. Pharmacol. Ther., 47, 403-411.
5. Shou, M., Korzekwa, K. R., Crespi, C. L., Gonzalez, F. J. and Gelboin, H. V. (1994) The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8- dihydrodiol. Mol. Carcinog., 10, 159-168.
6. Lee, C. R., Goldstein, J. A. and Pieper, J. A. (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 12, 251-263.
7. Yasar, U., Eliasson, E., Forslund-Bergengren, C., Tybring, G., Gadd, M., Sjoqvist, F. and Dahl, M. L. (2001) The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol., 57, 729-735.
8. Ohashi, Y., Yamada, K., Takemoto, I., Mizutani, T. and Saeki, K. (2005) Inhibition of human cytochrome P450 2E1 by halogenated anilines, phenols, and thiophenols. Biol. Pharm. Bull., 28, 1221-1223.
9. Ohashi, Y., Kato, T., Yamada, K., Mizutani, T. and Saeki, K. (2006) Cytochrome P450 2E1/2A6-Selective Inhibition by Halogenated Anilines on Metabolic Activation of Dimethylnitrosamine in Human Liver Microsomes. J. Health Sci., 52, 623-627.
10. Saeki, K., Tomomitsu, M., Kawazoe, Y., Momota, K. and Kimoto, H. (1996) Fluorinated benzo[h]quinolines and benzo[f]quinolines. Chem. Pharm. Bull., 44, 2254-2258.
11. Relling, M. V., Aoyama, T., Gonzalez, F. J. and Meyer, U. A. (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther., 252, 442-447.
12. Wu, W., Saeki, K. and Kawazoe, Y. (1995) Effect of fluorine-substitution on basicity of benzo[h]quinoline, benzo[f]quinoline, and quinoline. Heterocycles, 41, 315-322.